RRMS

About a third of people with relapsing-remitting multiple sclerosis (RRMS) exhibit cognitive impairments, according to a review by Australian researchers of 50 previously published studies. The findings suggest that cognitive issues might be somewhat less common in RRMS than previous reports have indicated, with prior estimates ranging from approximately…

A subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab) received approval from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with multiple sclerosis (MS). The approval means that people with relapsing forms of MS and those with primary progressive MS (PPMS) will now be…

The European Commission has approved a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab) to treat adults with multiple sclerosis (MS). The approval makes the new formulation available in the European Union for the same indications as the original intravenous (into-the-vein) formulation, which is available to people with relapsing…

Siemens Healthineers has received the CE mark in Europe for a lab-based blood test that measures the levels of neurofilament light chain, known as NfL — a protein that gets released into the bloodstream upon damage to nerve cells — in adults with relapsing forms of multiple sclerosis…

England’s National Institute for Health and Care Excellence (NICE) has updated its guidance on the use of Mavenclad (cladribine) in people with aggressive relapsing-remitting multiple sclerosis (RRMS) in ways that should help eligible patients be able to access the medication sooner. The new guidelines have less stringent…

Certain biomarkers in the cerebrospinal fluid (CSF) — the fluid surrounding the brain and spinal cord — around the time of a multiple sclerosis (MS) diagnosis may help predict the time to reaching certain disability milestones among people with a relapsing-remitting (RRMS) disease course, according to findings from…

Many of my personal breakthroughs and discoveries occurred during college, when I was living in a new city as a young adult with relapsing-remitting multiple sclerosis (RRMS). One of those “aha!” moments was understanding that saying no takes practice, but it’s a necessary aspect of life. A few…

A lower dose of the experimental oral therapy vidofludimus calcium (IMU-838) was not as effective as higher doses at reducing lesions in people with relapsing-remitting multiple sclerosis (RRMS), extended data from the therapy’s Phase 2 EMPhASIS trial show. “We found that doses of 30 mg and 45 mg,…

A subcutaneous (under-the-skin) formulation of Ocrevus (ocrelizumab) helped most adults with multiple sclerosis (MS) remain free of clinical relapses and new or worsening brain lesions, according to one-year data from the Phase 3 OCARINA II study. Given twice a year as a 10-minute injection, this formulation of Ocrevus…

Viatris has launched a generic version of low-dose Copaxone (glatiramer acetate) in the Canadian market for the treatment of people with relapsing-remitting multiple sclerosis (RRMS) who retain the ability to walk. Called Glatiramer Acetate Injection 20 mg/mL, the product was approved in Canada as a generic of…

Two years of treatment with Briumvi (ublituximab) in clinical trials resulted in a confirmed reduction in disability for more than 1 in 10 people with early relapsing multiple sclerosis (MS) who had not received any prior treatment. That’s according to new data from the ULTIMATE Phase 3 trials,…

Upon commencing my undergraduate studies at the University of Texas (UT) at Austin, I pursued a major in prehealth neuroscience. I had decided to pursue this degree shortly after my diagnosis of relapsing-remitting multiple sclerosis in 2016, during my senior year of high school. My hope in choosing the…

Ocrevus (ocrelizumab) continued to prevent disability progression among people with relapsing and progressive forms of multiple sclerosis (MS) over 10 years, according to clinical trial analyses. The most pronounced benefits were observed in patients who started on the therapy in the controlled part of the trials, compared with…

For people recently diagnosed with multiple sclerosis (MS), first-line treatment with Kesimpta (ofatumumab) was associated with a lower risk of disability progression over starting it after about 2.5 years of using Aubagio (teriflunomide). That’s according to six years of data spanning the ASCLEPIOS I (NCT02792218) and…

Long-term treatment with Clene Nanomedicine‘s experimental oral therapy CNM-Au8 led to signs of sustained improvements in nerve and myelin health for people with relapsing-remitting multiple sclerosis (RRMS) over three years, according to new data from the VISIONARY-MS clinical trial. The findings continue to support Clene’s plans to…

Ocrevus (ocrelizumab) had similar benefits in Black and Hispanic multiple sclerosis (MS) patients as earlier clinical trials with white patients did, one-year data from the CHIMES clinical trial indicates. About half of the CHIMES participants achieved no evidence of disease activity, or NEDA, which is defined as the…

A globally recognized neurologist and scientist at the University of California, Los Angeles (UCLA), has won the 2024 John Dystel Prize for Multiple Sclerosis Research for her work to improve women’s care through a better understanding of the mechanisms behind sex differences in multiple sclerosis (MS). Rhonda Voskuhl,…

Researchers have identified three distinct immune signatures in the blood of people with early multiple sclerosis (MS) that seem to be linked to specific disease trajectories and response to treatment, potentially offering a path to personalized care. “These findings represent a pivotal shift towards precision medicine in MS,” Heinz Wiendl,…

The prescribing label for Mavenclad (cladribine) in Great Britain has been extended to include the treatment of adults with active relapsing forms of multiple sclerosis (MS), as defined by clinical or imaging features. This decision made the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) the first to…

Older adults with multiple sclerosis (MS) whose eating habits resemble a Mediterranean diet tend to have less disability and better quality of life, a study found. The findings suggest the Mediterranean diet is a “promising nutritional intervention to slow down disease progression of MS and to minimize disease-related symptoms…

The Swank and Wahls diets, which are used by people with multiple sclerosis (MS), were associated with improvements in cognition and fatty acid blood profiles in relapsing-remitting MS (RRMS) patients, according to new analyses from the WAVES trial. Changes in omega-3 fatty acids after about three months correlated…

Multiple sclerosis (MS) patients diagnosed in more recent years — specifically after 2017 — were more likely to start sooner on a first MS disease-modifying therapy (DMT) than were those diagnosed between 2014 and 2016, an analysis of data from three large MS registries found. However, starting with…

Lynne Denise, right, and her dad, Don Collins, attend last year’s MS walk in Edwardsville, Illinois. (Photos courtesy of Lynne Denise) Day 30 of 31 This is Lynne Denise’s story: Hello, multiple sclerosis (MS) warriors! My name is Lynne Brush, and I was diagnosed with relapsing-remitting…

Low levels of the estrogen hormone estradiol may be linked to worse brain damage, a new study found, offering a possible explanation as to why multiple sclerosis (MS) often progresses more rapidly in women during menopause, when levels of that sex hormone drop. However, the use of hormone…

The U.S. Food and Drug Administration (FDA) has accepted SetPoint Medical, which is developing a nerve stimulator for people with relapsing-remitting multiple sclerosis (RRMS), into a pilot program designed to promote the development of new medical devices, the company said. The Total Product Life Cycle Advisory Program…

Rochelle waits for a virtual appointment with her doctor in 2020. (Photos courtesy of Rochelle) Day 25 of 31 This is Rochelle’s story: I’m writing this on the anniversary of “that day.” I was diagnosed with relapsing-remitting multiple sclerosis, or RRMS, in March 2020. How fitting that I…

Desiree Lama graduates from the University of Texas at Austin. (Photos courtesy of Desiree Lama) Day 24 of 31 This is Desiree Lama’s story: My journey with relapsing-remitting multiple sclerosis (RRMS) began when I was only 14 years old. I can vividly recall the smells, sights (or lack…

The U.S. Food and Drug Administration has designated SetPoint Medical’s neurostimulator a breakthrough device for the treatment of relapsing-remitting multiple sclerosis (RRMS). This designation is intended to accelerate the development of devices intending to more effectively treat or diagnose life-threatening or chronically debilitating diseases than standard approaches.

The U.S. Food and Drug Administration (FDA) has decided not to approve an application seeking clearance of GA Depot — a long-acting formulation of glatiramer acetate — for the treatment of relapsing forms of multiple sclerosis (MS). Importantly, this is not a rejection of the application for the…

People with relapsing forms of multiple sclerosis (MS) being treated with an infusion CD20 inhibitor such as Ocrevus (ocrelizumab) can safely transition to the more recent Briumvi (ublituximab-xiiy), which is given in shorter infusion times. That’s according to data from the ENHANCE Phase 3b clinical trial…